Through Amerinet, Resonant Medical expects to provide hospitals and cancer clinics with the Clarity System, an FDA-cleared solution that is both non-invasive and non-ionising for Image-Guided Radiation Therapy (IGRT) for soft tissue cancers, such as prostate and breast.
The Clarity System represents an evolution in radiation treatment imaging for soft tissue cancers by enabling radiation oncologists to visualise the target anatomy during each step of the patient flow from simulation, planning through treatment.
The three-year agreement expects to allow all Amerinet members to purchase the Clarity System for soft tissue IGRT under the cost effective product configuration solutions of the contract. As part of the contract launch, Amerinet will be sponsoring a ‘Target Buy’ Program for all of its member facilities.
The Target Buy opportunity will include special incentives to all member customers who wish to purchase the Soft Tissue IGRT technology during the months of May and June.
The Clarity Soft Tissue IGRT System provides a solution for any radiation oncology center. The advanced technology is compatible with any make, model or year of linear accelerator and CT scanner.
Stephen Whisenhunt, vice president of global sales and marketing at Resonant Medical, said: “Our collaboration with Amerinet demonstrates our commitment to helping cancer centers advance patient care by making significant improvements in radiation therapy planning, verification and delivery.
“We are excited to partner with Amerinet to support a more streamlined, efficient process for medical institutions adopting the Clarity System and integrating the technology into their radiation therapy planning and treatment delivery protocols.”
